EPIGENETIC THERAPY AUGMENTS DOCETAXEL IN THE TREATMENT OF BREAST CANCER: AN IN VITRO AND IN VIVO EVALUATION
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: JAIN, Prateek (MCOPS, Manipal University, Manipal, India)
- Co-author(s): Prateek Jain
Docetaxel (DTX) is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Unfortunately, there is altered response to DTX due to resistance. DNA methylation, an epigenetic event, plays a vital role in cancer and chemotherapy drug resistance. Exploiting the gene reactivation by using epigenetically acting agents in.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.